BMY Decision Brief — research Bristol Myers before you trade it

Business quality of Bristol Myers: 100/100

The Berkshire-style checklist scores BMY in the "very high" band — clears nearly every rule-based Berkshire-style criterion — typically durable profitability, a manageable debt structure, and strong cash conversion over the scanned window.

Important: this score measures business quality only, not whether today's price is fair. A 90+ quality stock can still be expensive enough to be a bad deal, and a 40-quality stock can be cheap enough to compensate you for the risk. That separation is exactly why the workflow treats quality and price as two different questions that only meet at the valuation ceiling.

The valuation ceiling: the price you shouldn't pay past

Working value analysis doesn't ask "will Bristol Myers grow?" It asks "what does $66.95 already assume?" Our two-stage residual-income model turns those assumptions into a single ceiling number. Below the ceiling you are paying a discount; above it you are paying for hope. Neither is automatically wrong — the point is knowing which one you're doing.

Run BMY's numbers yourself at the free Berkshire intrinsic value calculator — every input is documented, and you can adjust each assumption to match your own view.

How to read the LONG signal on BMY

• Status: LONG — the timing engine saw a constructive structure pass its criteria as of scan 2026-08-27.
• Age: 201 bars — an aging signal: the original reason may have expired, so run a fresh brief before relying on it.
• uPnL +43.6% · total return +29.0% — cumulative performance of the signal inside our system. It measures how the engine has behaved historically, not a forecast for you.

The right order: quality passes first → the ceiling is acceptable → thesis breaks are written down → then look at the signal. Looking at the signal first and hunting for reasons afterward is confirmation bias, and it gets everyone.

What would break the Bristol Myers thesis (a template for Healthcare)

Before investing real money, write your own break-conditions down. Common templates analysts use for Healthcare names:

1. The flagship drug/device loses exclusivity or loses share to generics
2. A pivotal trial fails beyond the timeline the price assumes
3. Government pricing or industry-tax policy shifts
4. A major consolidation changes payer bargaining power

The point is not the list above — it's that you write yours before buying. Conditions written while you own nothing are always colder than conditions written while you are down.

Healthcare peers on Balance Labs (US)

• Agilent (A) — quality 100 · signal LONG · compare BMY vs A
• AbbVie (ABBV) — quality 100 · signal LONG · compare BMY vs ABBV
• Abbott (ABT) — quality 100 · signal LONG · compare BMY vs ABT

Terms used on this page

• Quality score — a 0-100 rule-based Berkshire-style checklist grade (earnings consistency, debt structure, cash conversion). BMY: 100 as of scan 2026-08-27.
• Valuation ceiling — the highest price your thesis can pay without underpaying for risk, computed with a documented two-stage residual-income model.
• Signal / Side — the timing engine's status as of the snapshot: LONG, SHORT, or WAIT. BMY: LONG.
• uPnL — unrealized profit/loss accumulated by an open signal, measured from its entry price. Not your personal return.
• Age (bars) — price bars since the signal started. BMY: 201.
• Thesis break — a measurable event that should change your mind. Written before you buy, not after.